8 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
Accrued expenses and other current liabilities consists of the following (in thousands):
March 31, 2024 | December 31, 2023 | |||||||
Rebates, chargebacks, other customer fees and returns | $ | 84,803 | $ | 66,726 | ||||
Clinical accruals | 26,536 | 22,459 | ||||||
Contract manufacturing | 3,140 | 4,356 | ||||||
Commercial services | 5,309 | 6,900 | ||||||
Employee related expenses | 5,531 | 11,598 | ||||||
Other taxation and social security | 5,774 | 1,807 | ||||||
Other accruals | 7,456 | 5,989 | ||||||
$ | 138,549 | $ | 119,835 |
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
Product revenue, net from the sale of KIMMTRAK is presented by country / region based on the location of the end customer below (in thousands).
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
United States | $ | 50,026 | $ | 36,224 | ||||
Europe | 18,952 | 15,124 | ||||||
International | 1,364 | 233 | ||||||
Total product revenue, net | $ | 70,342 | $ | 51,581 |
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
Product revenue, net from the sale of KIMMTRAK is presented by country / region based on location of the end customer below (in thousands).
Three Months Ended March 31, | ||||||||||||||||
2024 | 2023 | Increase / (decrease) | % Increase / (decrease) | |||||||||||||
United States | $ | 50,026 | $ | 36,224 | $ | 13,802 | 38.1 | % | ||||||||
Europe | 18,952 | 15,124 | 3,828 | 25.3 | % | |||||||||||
International | 1,364 | 233 | 1,131 | 485.4 | % | |||||||||||
Total product revenue, net | $ | 70,342 | $ | 51,581 | $ | 18,761 | 36.4 | % |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Accrued expenses and other current liabilities consists of the following (in thousands):
2023 | 2022 | |||||||
Rebates, chargebacks, other customer fees and returns | $ | 66,726 | $ | 29,128 | ||||
Clinical accruals | 22,459 | 25,371 | ||||||
Contract manufacturing | 4,356 | 2,535 | ||||||
Commercial services | 6,900 | 5,761 | ||||||
Employee related expenses | 11,598 | 9,150 | ||||||
Other taxation and social security | 1,807 | 1,122 | ||||||
Other accruals | 5,989 | 3,680 | ||||||
$ | 119,835 | $ | 76,747 |
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
We have launched KIMMTRAK in 12 countries, including the United States, Germany, France and a number of other countries, and we are focused on driving increasing awareness and adoption of KIMMTRAK as a treatment for mUM amongst mUM patients and their healthcare providers. Our focus is to utilize our commercial capabilities to continue to meet patient demand in our major markets, and to launch in further markets in 2024. A breakdown of net product revenue from the sale of KIMMTRAK and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program is presented by country / region based on the location of the customer below.
2023 | 2022 | 2021 | ||||||||||
United States | $ | 169,791 | $ | 96,893 | $ | — | ||||||
Europe | 67,628 | 42,745 | 4,078 | |||||||||
International | 1,316 | 1,049 | — | |||||||||
Total revenue from the sale of therapies | $ | 238,735 | $ | 140,687 | $ | 4,078 |
10-K
2j28gqkalhcp903h as8
28 Feb 24
Annual report
7:33am
10-K
xjg9get0l92vmh0h59bk
28 Feb 24
Annual report
7:33am
10-K
z2h58tmnm
28 Feb 24
Annual report
7:33am
- Prev
- 1
- Next